Allergan Files Suit Against Alcon for Patent Infringement
IRVINE, Calif., Aug 24, 2004 (BUSINESS WIRE) -- Allergan, Inc. (NYSE:AGN) announced today that it has filed a patent infringement lawsuit against Alcon Laboratories, Inc., Alcon Research, Ltd. and Alcon, Inc. (NYSE:ACL) (collectively "Alcon"). The lawsuit was filed today in the U.S. District Court for the District of Delaware.
Allergan filed the lawsuit in response to Alcon's filing of a New Drug Application with the U.S. Food and Drug Administration under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. In the application, Alcon seeks to market a generic brimonidine tartrate ophthalmic solution 0.15% product in the United States. Brimonidine tartrate ophthalmic solution 0.15% is currently marketed by Allergan in the United States under Allergan's ALPHAGAN(R)P trademark.
Allergan filed the lawsuit on the basis that Alcon's proposed generic product infringes certain patents held by Allergan.
About Allergan, Inc.
Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the ophthalmology, neuromodulator, dermatology and other specialty markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives.
SOURCE: Allergan, Inc.
Allergan, Inc. Jim Hindman (Investors), 714-246-4636 Joann Bradley (Investors), 714-246-4766 Stephanie Fagan (Media), 714-246-5232
Customize your Business Wire news & multimedia to match your needs. Get breaking news from companies and organizations worldwide. Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.
News Provided by COMTEX